Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity

医学 卡铂 肿瘤科 癌肉瘤 内科学 子宫内膜癌 转移 肉瘤 淋巴结切除术 存活率 化疗 癌症 外科 癌 顺铂 病理
作者
Shinya Matsuzaki,Maximilian Klar,Satoko Matsuzaki,Lynda D. Roman,Anil K. Sood,Koji Matsuo
出处
期刊:Gynecologic Oncology [Elsevier BV]
卷期号:160 (2): 586-601 被引量:140
标识
DOI:10.1016/j.ygyno.2020.10.043
摘要

Uterine carcinosarcoma (UCS) is a biphasic aggressive high-grade endometrial cancer in which the sarcoma element has de-differentiated from the carcinoma element. UCS is considered a rare tumor, but its incidence has gradually increased in recent years (annual percent change from 2000 to 2016 1.7%, 95% confidence interval 1.2–2.2) as has the proportion of UCS among endometrial cancer, exceeding 5% in recent years. UCS typically affects the elderly, but in recent decades patients became younger. Notably, a stage-shift has occurred in recent years with increasing nodal metastasis and decreasing distant metastasis. The concept of sarcoma dominance may be new in UCS, and a sarcomatous element >50% of the uterine tumor is associated with decreased survival. Multimodal treatment is the mainstay of UCS. Lymphadenectomy, chemotherapy, and brachytherapy have increased in the past few decades, but survival outcomes remain dismal: the median survival is less than two years, and the 5-year overall survival rate has not changed in decades (31.9% in 1975 to 33.8% in 2012). Carboplatin/paclitaxel adjuvant chemotherapy improves progression-free survival compared with ifosfamide/paclitaxel, particularly in stages III-IV disease (GOG-261 trial). Twenty-six clinical trials previously examined therapeutic effectiveness in recurrent/metastatic UCS. The median response rate and progression-free survival were 37.5% and 5.9 months, respectively, after first-line therapy, but after later therapies, the outcomes were far worse (5.5% and 1.8 months, respectively). One significant discovery was that epithelial-mesenchymal transition (EMT) plays a pivotal role in the pathogenesis of sarcomatous dedifferentiation in UCS and that heterologous sarcoma is associated with a higher EMT signature compared with homologous sarcoma. Furthermore, next-generation sequencing has revealed that UCS tumors are serous-like and that common somatic mutations include those in TP53, PIK3CA, FBXW7, PTEN, and ARID1A. This contemporary review highlights recent clinical and molecular updates in UCS. A possible therapeutic target of EMT in UCS is also discussed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
2秒前
3秒前
慕青的应助被阿瞒采纳,获得10
4秒前
汉堡包的应助被qingtian采纳,获得10
4秒前
ZZICU完成签到,获得积分10
4秒前
laimeng完成签到 ,获得积分10
4秒前
5秒前
cc发布了新的文献求助20
5秒前
风吹麦浪的应助被天真山柳采纳,获得10
6秒前
6秒前
Aragon完成签到,获得积分10
7秒前
汉堡包的应助被675675采纳,获得30
8秒前
8秒前
Lighter发布了新的文献求助10
8秒前
乌龙茶发布了新的文献求助10
9秒前
SciGPT的应助被333采纳,获得10
9秒前
甜甜紫寒完成签到 ,获得积分10
11秒前
天真山柳完成签到,获得积分20
12秒前
林端完成签到,获得积分10
13秒前
13秒前
满意曼寒完成签到,获得积分10
14秒前
现代宛丝发布了新的文献求助10
14秒前
14秒前
柯镇恶完成签到,获得积分10
14秒前
zhuang完成签到,获得积分10
15秒前
15秒前
苹果发布了新的文献求助10
16秒前
稀西完成签到,获得积分10
17秒前
17秒前
小田完成签到 ,获得积分10
18秒前
18秒前
甜美的谷云完成签到 ,获得积分10
19秒前
21秒前
冷酷画板完成签到,获得积分20
22秒前
月亮喜欢吃月饼完成签到 ,获得积分10
22秒前
忧郁的汉堡完成签到,获得积分10
22秒前
强小强努力努力完成签到,获得积分10
22秒前
Lyuoah完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181767
求助须知:如何正确求助?哪些是违规求助? 9571480
关于积分的说明 21818225
捐赠科研通 7778030
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479598